Reply to thread

Message

The study is already underway double blind placebo controlled, 75,000 patients randomized to Tudorza, Spiriva, and placebo. Six month results show statistical superiority for Tudorza vs. Spiriva and placebo on the endpoints of trough FEV1 improvement and reductions in COPD exacerbations. One year trial results will be finished in December. Paper should be published in NEJM early spring.

[QUOTE="Anonymous, post: 4542180"] The study is already underway double blind placebo controlled, 75,000 patients randomized to Tudorza, Spiriva, and placebo. Six month results show statistical superiority for Tudorza vs. Spiriva and placebo on the endpoints of trough FEV1 improvement and reductions in COPD exacerbations. One year trial results will be finished in December. Paper should be published in NEJM early spring. [/QUOTE]

Name

Verification